These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 2260923)

  • 21. Chimeric yellow fever virus 17D-Japanese encephalitis virus vaccine: dose-response effectiveness and extended safety testing in rhesus monkeys.
    Monath TP; Levenbook I; Soike K; Zhang ZX; Ratterree M; Draper K; Barrett AD; Nichols R; Weltzin R; Arroyo J; Guirakhoo F
    J Virol; 2000 Feb; 74(4):1742-51. PubMed ID: 10644345
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analysis of C-terminally truncated dengue 2 and dengue 3 virus envelope glycoproteins: processing in insect cells and immunogenic properties in mice.
    Delenda C; Staropoli I; Frenkiel MP; Cabanié L; Deubel V
    J Gen Virol; 1994 Jul; 75 ( Pt 7)():1569-78. PubMed ID: 8021588
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunization of mice with recombinant vaccinia virus expressing authentic dengue virus nonstructural protein NS1 protects against lethal dengue virus encephalitis.
    Falgout B; Bray M; Schlesinger JJ; Lai CJ
    J Virol; 1990 Sep; 64(9):4356-63. PubMed ID: 2143542
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates.
    Guirakhoo F; Pugachev K; Arroyo J; Miller C; Zhang ZX; Weltzin R; Georgakopoulos K; Catalan J; Ocran S; Draper K; Monath TP
    Virology; 2002 Jun; 298(1):146-59. PubMed ID: 12093182
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Construction and biological properties of yellow fever 17D/dengue type 1 recombinant virus.
    Mateu GP; Marchevsky RS; Liprandi F; Bonaldo MC; Coutinho ES; Dieudonné M; Caride E; Jabor AV; Freire MS; Galler R
    Trans R Soc Trop Med Hyg; 2007 Mar; 101(3):289-98. PubMed ID: 17169387
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Structural and functional properties of the 14-kDa envelope protein of vaccinia virus synthesized in Escherichia coli.
    Lai CF; Gong SC; Esteban M
    J Biol Chem; 1990 Dec; 265(36):22174-80. PubMed ID: 2266120
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of protective immunity elicited by recombinant vaccinia viruses that synthesize E or NS1 of Japanese encephalitis virus.
    Konishi E; Pincus S; Fonseca BA; Shope RE; Paoletti E; Mason PW
    Virology; 1991 Nov; 185(1):401-10. PubMed ID: 1833876
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preliminary evaluation of DNA vaccine candidates encoding dengue-2 prM/E and NS1: their immunity and protective efficacy in mice.
    Lu H; Xu XF; Gao N; Fan DY; Wang J; An J
    Mol Immunol; 2013 Jun; 54(2):109-14. PubMed ID: 23270684
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunogenicity of a purified fragment of 17D yellow fever envelope protein.
    Brandriss MW; Schlesinger JJ; Walsh EE
    J Infect Dis; 1990 Jun; 161(6):1134-9. PubMed ID: 1693159
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Induction of protective immunity with antibody to herpes simplex virus type 1 glycoprotein H (gH) and analysis of the immune response to gH expressed in recombinant vaccinia virus.
    Forrester AJ; Sullivan V; Simmons A; Blacklaws BA; Smith GL; Nash AA; Minson AC
    J Gen Virol; 1991 Feb; 72 ( Pt 2)():369-75. PubMed ID: 1704412
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 17D yellow fever vaccine virus envelope protein expressed by recombinant baculovirus is antigenically indistinguishable from authentic viral protein.
    Shiu SY; Morikawa S; Buckley A; Higgs S; Karunakarannair V; Blachere C; Gould EA
    J Gen Virol; 1991 Jun; 72 ( Pt 6)():1451-4. PubMed ID: 1710651
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The synergistic effect of combined immunization with a DNA vaccine and chimeric yellow fever/dengue virus leads to strong protection against dengue.
    Azevedo AS; Gonçalves AJ; Archer M; Freire MS; Galler R; Alves AM
    PLoS One; 2013; 8(3):e58357. PubMed ID: 23472186
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Protection of mice against yellow fever virus encephalitis by immunization with a vaccinia virus recombinant encoding the yellow fever virus non-structural proteins, NS1, NS2a and NS2b.
    Putnak JR; Schlesinger JJ
    J Gen Virol; 1990 Aug; 71 ( Pt 8)():1697-702. PubMed ID: 2144016
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of chimeric DNA vaccines consisting of premembrane and envelope genes of Japanese encephalitis and dengue viruses as a strategy for reducing induction of dengue virus infection-enhancing antibody response.
    Sjatha F; Kuwahara M; Sudiro TM; Kameoka M; Konishi E
    Microbiol Immunol; 2014 Feb; 58(2):126-34. PubMed ID: 24372832
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A DNA vaccine candidate encoding the structural prM/E proteins elicits a strong immune response and protects mice against dengue-4 virus infection.
    Lima DM; de Paula SO; França RF; Palma PV; Morais FR; Gomes-Ruiz AC; de Aquino MT; da Fonseca BA
    Vaccine; 2011 Jan; 29(4):831-8. PubMed ID: 21115054
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vaccination of BALB/c mice with Escherichia coli-expressed vaccinia virus proteins A27L, B5R, and D8L protects mice from lethal vaccinia virus challenge.
    Berhanu A; Wilson RL; Kirkwood-Watts DL; King DS; Warren TK; Lund SA; Brown LL; Krupkin AK; Vandermay E; Weimers W; Honeychurch KM; Grosenbach DW; Jones KF; Hruby DE
    J Virol; 2008 Apr; 82(7):3517-29. PubMed ID: 18199639
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Louping ill virus envelope protein expressed by recombinant baculovirus and vaccinia virus fails to stimulate protective immunity.
    Shiu SY; Reid HW; Gould EA
    Virus Res; 1992 Dec; 26(3):213-29. PubMed ID: 1337231
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine.
    Guirakhoo F; Arroyo J; Pugachev KV; Miller C; Zhang ZX; Weltzin R; Georgakopoulos K; Catalan J; Ocran S; Soike K; Ratterree M; Monath TP
    J Virol; 2001 Aug; 75(16):7290-304. PubMed ID: 11462001
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A MVA construct expressing a secretable form of the Dengue virus 3 envelope protein protects immunized mice from dengue-induced encephalitis.
    Quinan BR; Versiani AF; da Fonseca FG
    Vaccine; 2016 Dec; 34(50):6120-6122. PubMed ID: 27817963
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Structural proteins of hog cholera virus expressed by vaccinia virus: further characterization and induction of protective immunity.
    Rümenapf T; Stark R; Meyers G; Thiel HJ
    J Virol; 1991 Feb; 65(2):589-97. PubMed ID: 1987372
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.